Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for prevention of letrozole-associated bone loss in postmenopausal hormone receptor-positive breast cancer
2004-004796-11Phase 3Completed
- Sponsor
- Universitätsklinikum Augsburg
- Start
- Jan 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zoledronic acid and letrozole in breast cancer and osteoporosis, sponsored by Universitätsklinikum Augsburg. Primary endpoint: Lumbar spine bone mineral density at 12 months. Started Jan 2007; status: completed.
02
Drugs
zoledronic acidletrozole
03
Conditions
breast cancerosteoporosis
Beyond the preview
Go deeper on 2004-004796-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004796-11.